2. Gupta K el al. 2011. Clinical Infectious Diseases. March 2011;52(5):103–120.

3. Naber K.G., Alidzhanov Zh.F. Are there alternatives to antibiotic therapy and prevention for uncomplicated urinary tract infections? Urologiia. 2014;№ 6:5–13. Russian (Naber K.G., Алиджанов Ж.Ф. Существуют ли альтернативные методы антибактериальной терапии и профилактики неосложненных инфекций мочевыводящих путей? Урология. 2014;6:5–13).

4. Antimicrobial therapy and prevention of infections of the kidney, urinary tract and male genitals. Federal’nyye klinicheskiye rekomendatsii. M., 2020, 110 p. Russian (Федеральные клинические рекомендации «Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов». М., 2020, 110 с.).

5. Balan V.Ye., Sinyakova L.A., Bogdashevskaya O.V. Рod red. V.Ye. Radzinskyi. Disturbances of the vaginal biotope at different periods of a woman’s life: association with urinary disorders. A view of a gynecologist and urologist on the causes and principles of treatment of genitourinary disorders. M.: Redaktsiya zhurnala Status Praesens, 2018. p. 3. Russian (Балан В.Е., Синякова Л.А., Богдашевская О.В. Под ред. В.Е. Радзинского. Нарушения биотопа влагалища в разные периоды жизни женщины: связь с дизурическими расстройствами. Взгляд гинеколога и уролога на причины и принципы лечения генитоуринарных расстройств. М.: Редакция журнала Status Praesens, 2018. С. 3).

6. Flores-Mireles A.L., Walker J.N., Caparon M. et al. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 2015;13(5):269–284.

7. Vouloumanou E.K., Karageorgopoulos D.E., Kazantzi M.S., Kapaskelis A.M., Falagas M.E. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. J Infect 2009;64(1):16–24.

8. Ny S., Edquist P., Dumpis U., et al. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J Glob Antimicrob Resist. 2019; 17:25–34.

9. Palagin I.S. et al. Antibiotic resistance among pathogens causing community-acquired urinary tract infections in Russia: results of the International Multicenter Study “Darmis-2018”. Klinicheskaya mikrobiologiia i antimikrobnaya khimioterapiia. 2019;21(2):134–1469. Russian (Палагин И.С. и соавт. Антибиотрикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исседования «ДАРМИС-2018». Клиническая микробиология и антимикробная химиотерапия. 2019;21(2):134–1469).

10. Fihn S.D. et al. Am J Epidemiol 1996; 144 (5):512–520.

11. Brown P.D. et al. Clin Infect Dis 2002; 34 (8):1061–1066.

12. Hooton T.M. et al. New Engl J Med 1996; 335:468–474.

13. Stamm W.E. In Harrisons Infections Diseases 2010:272–282.

14. Palagin I.S. et al. Klinicheskaya mikrobiologiia i antimikrobnaya khimioterapiia. 2012; 14(4): 280-302. Russian (Палагин И.С. и соавт. Клиническая микробиология и антимикробная химиотерапия. 2012;14(4):280–302).

15. Cai T., Tamanini I. et al. J Urol 2020;203(3):570–578.

16. Marchese A., Gualco L., Debbia E.A., et al. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents. 2003;22:53–59.

17. Schito G.C. Attività in vitro di fosfomicina nei confronti di patogeni urinari Gram negativi di recente isolamento. Presented at the 21st Congresso Nazionale della Società Italiana di Chemioterapia, Florence, 1–5 December 2001.

18. Szozda G. Nowakowska K. Pawluch D. Comparative evaluation of the antibacterial activity of nitrofuran derivatives Polski Tygodnik Lekarski (Warsaw, Poland: 1960). 1987,42(31–32):967–969.

19. Paul H.E., Paul M.F. The Nitrofurans – Chemotherapeutic properties. –Experimental Chemotherapy, Ed. Schnitzer R.J., Hawking F., vol. II, Chemotherapy of bacterial infections, Part I, Academic Press, N.-Y.–L., 1964; 307–370.

20. Perepanova T.S. Nitrofurans in urological practice: are they all the same and why do we start prescribing them again? Eksperimental’naya i klinicheskaya urologiya. 2018;3:91–101. Russian (Перепанова Т. С. Нитрофураны в урологической практике: все ли они одинаковы и почему мы возвращаемся к ним сегодня? Экспериментальная и клиническая урология. 2018;3:91–101).

21. Olender D., Zwawiak J., Zaprutko L. Pharmaceuticals (Basel). 2018;11(2):54. Doi: 10.3390/ph11020054.

22. Bains A., Buna D., Hoag N.A. A retrospective review assessing the efficacy and safety of nitrofurantoin in renal impairment. Can. Pharm. J. 2009;142:248–252.

23. Cunha B.A., Schoch P.E., Hage J.R. Nitrofurantoin: preferred empiric therapy for community-acquired lower urinary tract infections. Mayo Clin. Proc. 2011;86:1243–1244.

24. El-Zaher A.A., Mahrouse M.A. A validated spectrofluoremetric method for the determination of nifuroxazide through coumarin formation using experimental design. Chem. Cent. J. 2013;7:90.

25. Smith P., Heimer G., Norgren A. Steroid hormone receptors in pelvic muscles and ligaments in women. Gynecol. Obstet. Invest. 1990;30(1):27–30.

26. Portman D.J., Gass M.L. Vulvovaginal atrophy terminology consensus conference panel. Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International society for the study of women’s sexual health and the North American menopause society. Maturitas. 2014;79(3):349–354.